首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.
【24h】

The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.

机译:钙和维生素D3联合添加对中度CKD血清完整甲状旁腺激素的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Studies addressing the effects of vitamin D(3) supplementation on secondary hyperparathyroidism in patients with moderate chronic kidney disease are scarce. STUDY DESIGN: Post hoc analysis of the randomized clinical trial Vitamin D, Calcium, Lyon Study II (DECALYOS II) to assess effects according to baseline estimated glomerular filtration rate (eGFR). SETTING & PARTICIPANTS: Multicenter, randomized, double-blinded, placebo-controlled study of 639 elderly women randomly assigned to calcium-vitamin D(3) fixed combination; calcium plus vitamin D(3) separate combination, or placebo. INTERVENTIONS: Placebo or calcium (1,200 mg) and vitamin D(3) (800 IU) in fixed or separate combination. OUTCOMES & MEASUREMENTS: Proportion of participants with a mean decrease in intact parathyroid hormone (iPTH) level of 30% or greater. eGFR was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) Study equation and categorized as 60 or greater, 45 to 59, and less than 45 mL/min/1.73 m(2). RESULTS: 610 participants had an eGFR at baseline: 288 (47.2%), 222 (36.4%), and 100 (16.4%) were in each decreasing eGFR category. Across decreasing eGFR groups, 88%, 86%, and 89% had 25-hydroxyvitamin D (25[OH]D) levels less than 15 ng/mL at baseline. On treatment, similar improvements in the proportion of participants achieving 25(OH)D levels greater than 30 ng/mL at 6 months were seen in all kidney function groups (43%, 49%, and 41%, respectively). Active regimens versus placebo increased mean 25(OH)D levels from baseline in all eGFR groups at all times (P < 0.001 for all). The proportion with a 30% or greater decrease in iPTH level at 6 months was 50% in all eGFR groups on treatment versus 6% to 9% for placebo (P < 0.001 for all). The effects of the intervention on iPTH levels did not differ according to baseline eGFR (interaction P > 0.1 for all times). LIMITATIONS: This study included only elderly white women. CONCLUSION: Vitamin D(3) was effective in increasing 25(OH)D and decreasing iPTH levelsin patients with moderate chronic kidney disease.
机译:背景:关于中度慢性肾脏病患者补充维生素D(3)对继发性甲状旁腺功能亢进的影响的研究很少。研究设计:对随机临床试验维生素D,钙,里昂研究II(DECALYOS II)进行事后分析,以根据基线估计的肾小球滤过率(eGFR)评估疗效。地点与参与者:随机分配钙-维生素D(3)固定组合的639名老年妇女的多中心,随机,双盲,安慰剂对照研究;钙加维生素D(3)的单独组合或安慰剂。干预措施:安慰剂或钙(1200毫克)和维生素D(3)(800 IU)以固定或分开的组合形式使用。结果与测量:完整甲状旁腺激素(iPTH)水平平均降低30%或更多的参与者比例。 eGFR使用肾脏疾病饮食的4变量修改(MDRD)研究公式计算得出,分为60或更高,45到59和小于45 mL / min / 1.73 m(2)。结果:610名参与者的eGFR处于基线:每种eGFR下降类别中的288(47.2%),222(36.4%)和100(16.4%)。在下降的eGFR组中,有88%,86%和89%的25-羟基维生素D(25 [OH] D)水平在基线时低于15 ng / mL。在治疗中,在所有肾功能组中,在6个月时达到25(OH)D水平高于30 ng / mL的受试者比例都有相似的改善(分别为43%,49%和41%)。积极方案与安慰剂相比,所有eGFR组在任何时候均比基线提高平均25(OH)D水平(所有P均<0.001)。在治疗的所有eGFR组中,iPTH在6个月时降低30%或更高的比例为50%,而安慰剂为6%至9%(所有P均<0.001)。干预对iPTH水平的影响没有根据基线eGFR的不同而变化(所有时间的相互作用P> 0.1)。局限性:本研究仅包括老年白人妇女。结论:维生素D(3)可有效增加中度慢性肾脏病患者的25(OH)D和降低iPTH水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号